Biochemical characterization of IMP-30, a metallo-β-lactamase with enhanced activity toward ceftazidime

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 5122-5126

  Pegg, Kevin M ^a   Liu, Eleanor M ^b   LaCuran, Alecander E ^b   Oelschlaeger, Peter ^b  

^a CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; IMP 1 PROTEIN; IMP 30 PROTEIN; LYSINE; METALLO BETA LACTAMASE; UNCLASSIFIED DRUG; WATER;

ANTIBIOTIC SENSITIVITY; ARTICLE; BIOCHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TURNOVER TIME;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFTAZIDIME; KINETICS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DYNAMICS SIMULATION; MUTATION;

EID: 84884235803     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02341-12     Document Type: Article

References (38)

1. Ambler RP. 1980. The structure of-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 289:321-331.
2. Shibata N, Doi Y, Yamane K, Yagi T, Kurokawa H, Shibayama K, Kato H, Kai K, Arakawa Y. 2003. PCR typing of genetic determinants for metallo-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J. Clin. Microbiol. 41:5407-5413.
3. Tysall L, Stockdale MW, Chadwick PR, Palepou MF, Towner KJ, Livermore DM, Woodford N. 2002. IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK. J. Antimicrob. Chemother. 49: 217-218.
4. Senda K, Arakawa Y, Ichiyama S, Nakashima K, Ito H, Ohsuka S, Shimokata K, Kato N, Ohta M. 1996. PCR detection of metallo-lactamase gene (blaIMP) in gram-negative rods resistant to broadspectrum-lactams. J. Clin. Microbiol. 34:2909-2913.
5. Oelschlaeger P, Ai N, Duprez KT, Welsh WJ, Toney JH. 2010. Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm? J. Med. Chem. 53:3013-3027.
6. Bush K. 2010. Alarming-lactamase-mediated resistance in multidrugresistant Enterobacteriaceae. Curr. Opin. Microbiol. 13:558-564.
7. Garau G, Garcia-Saez I, Bebrone C, Anne C, Mercuri P, Galleni M, Frere JM, Dideberg O. 2004. Update of the standard numbering scheme for class B-lactamases. Antimicrob. Agents Chemother. 48:2347-2349.
8. Cornaglia G, Giamarellou H, Rossolini GM. 2011. Metallo-lactamases: a last frontier for-lactams? Lancet Infect. Dis. 11:381-393.
9. Shevchenko OV, Edelstein MV. 2007. Epidemic population structure of MBL-producing Pseudomonas aeruginosa in Russia, abstr C2-1499. Abstr. 47th Interscience Conference on Antimicrob.Agents Chemother.
10. Concha NO, Janson CA, Rowling P, Pearson S, Cheever CA, Clarke BP, Lewis C, Galleni M, Frere JM, Payne DJ, Bateson JH, Abdel-Meguid SS. 2000. Crystal structure of the IMP-1 metallo-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor. Biochemistry 39:4288-4298.
11. Liu EM, Pegg KM, Oelschlaeger P. 2012. The sequence-activity relationship between the metallo-lactamases IMP-1, IMP-6, and IMP-25 suggests an evolutionary adaptation to meropenem exposure. Antimicrob. Agents Chemother. 56:6403-6406.
12. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. 2009. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J. Comput. Chem. 30:2785-2791.
13. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, Duke RE, Luo R, Crowley M, Walker RC, Zhang W, Merz KM, Wang B, Hayik S, Roitberg A, Seabra G, Kolossváry I, Wong KF, Paesani F, Vanicek J, Wu X, Brozell SR, Steinbrecher T, Gohlke H, Yang L, Tan C, Mongan J, Hornak V, Cui G, Mathews DH, Seetin MG, Sagui C, Babin V, Kollman PA. 2008. AMBER 10. University of California, San Francisco, CA.
14. Oelschlaeger P, Mayo SL, Pleiss J. 2005. Impact of remote mutations on metallo-lactamase substrate specificity: implications for the evolution of antibiotic resistance. Protein Sci. 14:765-774.
15. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
16. Hunt JB, Neece SH, Ginsburg A. 1985. The use of 4-(2 pyridylazo) resorcinol in studies of zinc release from Escherichia coli aspartate transcarbamoylase. Anal. Biochem. 146:150-157.
17. King DT, Worrall LJ, Gruninger R, Strynadka NC. 2012. New Delhi metallo-lactamase: structural insights into-lactam recognition and inhibition. J. Am. Chem. Soc. 134:11362-11365.
18. Laraki N, Franceschini N, Rossolini GM, Santucci P, Meunier C, de Pauw E, Amicosante G, Frere JM, Galleni M. 1999. Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-lactamase IMP-1 produced by Escherichia coli. Antimicrob. Agents Chemother. 43: 902-906.
19. Riccio ML, Franceschini N, Boschi L, Caravelli B, Cornaglia G, Fontana R, Amicosante G, Rossolini GM. 2000. Characterization of the metallo-lactamase determinant of Acinetobacter baumannii AC-54/97 reveals the existence of blaIMP allelic variants carried by gene cassettes of different phylogeny. Antimicrob. Agents Chemother. 44:1229-1235.
20. Gutkind GO, Di Conza J, Power P, Radice M. 2013.-Lactamasemediated resistance: a biochemical, epidemiological and genetic overview. Curr. Pharm. Des. 19:164-208.
21. Poirel L, Pitout JD, Nordmann P. 2007. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol. 2:501-512.
22. Samuelsen O, Castanheira M, Walsh TR, Spencer J. 2008. Kinetic characterization of VIM-7, a divergent member of the VIM metallo-lactamase family. Antimicrob. Agents Chemother. 52:2905-2908.
23. Franceschini N, Caravelli B, Docquier JD, Galleni M, Frere JM, Amicosante G, Rossolini GM. 2000. Purification and biochemical characterization of the VIM-1 metallo-lactamase. Antimicrob. Agents Chemother. 44:3003-3007.
24. Murphy TA, Simm AM, Toleman MA, Jones RN, Walsh TR. 2003. Biochemical characterization of the acquired metallo-lactamase SPM-1 from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 47:582-587.
25. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a new metallo-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53:5046-5054.
26. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 9th edition. M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
27. Osano E, Arakawa Y, Wacharotayankun R, Ohta M, Horii T, Ito H, Yoshimura F, Kato N. 1994. Molecular characterization of an enterobacterial metallo-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob. Agents Chemother. 38:71-78.
28. Frere JM. 1989. Quantitative relationship between sensitivity to-lactam antibiotics and-lactamase production in gram-negative bacteria. I. Steady-state treatment. Biochem. Pharmacol. 38:1415-1426.
29. Lakaye B, Dubus A, Lepage S, Groslambert S, Frere JM. 1999. When drug inactivation renders the target irrelevant to antibiotic resistance: a case story with-lactams. Mol. Microbiol. 31:89-101.
30. Griffin DH, Richmond TK, Sanchez C, Moller AJ, Breece RM, Tierney DL, Bennett B, Crowder MW. 2011. Structural and kinetic studies on metallo-lactamase IMP-1. Biochemistry 50:9125-9134.
31. Stote RH, Karplus M. 1995. Zinc binding in proteins and solution: a simple but accurate nonbonded representation. Proteins 23:12-31.
32. Irwin JJ, Raushel FM, Shoichet BK. 2005. Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry 44:12316-12328.
33. Wang Z, Fast W, Benkovic SJ. 1999. On the mechanism of the metallo-lactamase from Bacteroides fragilis. Biochemistry 38:10013-10023.
34. Koh TH, Yamaguchi K, Ishii Y. 2008. Characterisation of the metallo-lactamase VIM-6 and its genetic support. Int. J. Antimicrob. Agents 32:446-449.
35. Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN. 2009. Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-lactamase clones (VIM-2,-5,-6, and-11 and the newly characterized VIM-18). Antimicrob. Agents Chemother. 53:1225-1227.
36. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. 2004. Molecular characterization of a-lactamase gene, blaGIM-1, encoding a new subclass of metallo-lactamase. Antimicrob. Agents Chemother. 48: 4654-4661.
37. Rains CP, Bryson HM, Peters DH. 1995. Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 49:577-617.
38. Ishii Y, Eto M, Mano Y, Tateda K, Yamaguchi K. 2010. In vitro potentiation of carbapenems with ME1071, a novel metallo-lactamase inhibitor, against metallo-lactamase-producing Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 54:3625-3629.